Literature DB >> 34129821

Oncolytic virotherapy: Potentially a game-changing tumor treatment.

Tobias Kessler1, Wolfgang Wick2.   

Abstract

A two-center phase I trial published in the New England Journal of Medicine shows safety and feasibility of locally administered oncolytic herpes simplex virus-1 virus plus 5 Gy radiation for progressive pediatric high-grade gliomas. Patients seemed to have an unusually good clinical course and showed immune activation in post-treatment tissues.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2021        PMID： 34129821     DOI： 10.1016/j.ccell.2021.05.014

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  3 in total

1.  Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.

Authors:  Fei Ju; Yong Luo; Chaolong Lin; Xian Jia; Zilong Xu; Rui Tian; Yanhua Lin; Min Zhao; Yating Chang; Xiaoxuan Huang; Shaopeng Li; Wenfeng Ren; Yaning Qin; Mengqin Yu; Jizong Jia; Jinle Han; Wenxin Luo; Jun Zhang; Guo Fu; Xiangzhong Ye; Chenghao Huang; Ningshao Xia
Journal:  J Immunother Cancer       Date:  2022-06       Impact factor: 12.469

2.  Macrophage Distribution Affected by Virus-Encoded Granulocyte Macrophage Colony Stimulating Factor Combined with Lactate Oxidase.

Authors:  Chia-Chen Hsieh; Ming-Jung Hsieh; Yu-Hsin Wang; Zi-Xian Liao
Journal:  ACS Omega       Date:  2022-06-24

3.  From Immunosuppression to Immunomodulation - Turning Cold Tumours into Hot.

Authors:  Mariangela Garofalo; Katarzyna Wanda Pancer; Magdalena Wieczorek; Monika Staniszewska; Stefano Salmaso; Paolo Caliceti; Lukasz Kuryk
Journal:  J Cancer       Date:  2022-07-04       Impact factor: 4.478
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.